Loading organizations...
The U.S. Army Medical Research and Development Command (USAMRDC) serves as the Army's premier organization for military medical research, concentrating on delivering advanced medical solutions. It conducts extensive biomedical research to tackle the distinct health challenges encountered by warfighters, encompassing the development of treatments for infectious diseases and the provision of evidence-based care for personnel wounded in combat. The command's work directly informs and supports the health and readiness of military forces.
The command, or its direct predecessor, the U.S. Army Medical Research and Materiel Command (USAMRMC), has roots in earlier Army medical research endeavors, formally taking shape as a comprehensive research and development command around 1968. This evolution was driven by the critical insight that military personnel face unique health threats and injuries requiring dedicated, specialized scientific investigation and medical innovation to ensure their well-being and operational effectiveness.
USAMRDC's primary beneficiaries are U.S. military personnel, including warfighters and soldiers globally, whose health and readiness are paramount to national security. The command's long-term vision centers on continuously advancing medical capabilities to protect service members from emerging threats, improve combat casualty care, and optimize overall soldier performance, ensuring a medically ready force prepared for future challenges.
U.S. Army Medical Research and Development Command has 1 tracked investment across 1 company. The latest tracked deal is $11.9M Grant / Other Equity / Series A in Neuravi in July 2012.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 11, 2012 | Neuravi | $11.9M Grant / Other Equity / Series A | Delta Partners, Fountain Healthcare Partners | — |